Bacterial extract (OM-85) with human-equivalent doses does not inhibit the development of asthma in a murine model
Allergol. immunopatol
; 44(6): 504-511, nov.-dic. 2016. ilus, tab, graf
Artigo
em Inglês
| IBECS
| ID: ibc-157870
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
BACKGROUND:
OM-85 is an immunostimulant bacterial lysate, which has been proven effective in reducing the number of lower airways infections. We investigated the efficacy of the bacterial lysate OM-85 in the primary prevention of a murine model of asthma.METHODS:
In the first phase of our study the animals received doses of 0.5ìg, 5ìg and 50ìg of OM-85 through gavage for five days (days −10 to −6 of the protocol), 10 days prior to starting the sensitisation with ovalbumin (OVA), in order to evaluate the results of dose-response protocols. A single dose (5ìg) was then chosen in order to verify in detail the effect of OM-85 on the pulmonary allergic response. Total/differential cells count and cytokine levels (IL-4, IL-5, IL-13 and IFN-ã) from bronchoalveolar lavage fluid (BALF), OVA-specific IgE levels from serum, lung function and lung histopathological analysis were evaluated.RESULTS:
OM-85 did not reduce pulmonary eosinophilic response, regardless of the dose used. In the phase protocol using 5ìg/animal of OM-85, no difference was shown among the groups studied, including total cell and eosinophil counts in BALF, serum OVA-specific IgE, lung histopathologic findings and lung resistance. However, OM-85 decreased IL-5 and IL-13 levels in BALF.CONCLUSIONS:
OM-85, administered in early life in mice in human-equivalent doses, does not inhibit the development of allergic pulmonary response in miceRESUMEN
No disponible
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas
Problema de saúde:
Objetivo 9: Redução de doenças não transmissíveis
Base de dados:
IBECS
Assunto principal:
Asma
/
Adjuvantes Imunológicos
/
Inflamação
Tipo de estudo:
Estudo prognóstico
Limite:
Animais
Idioma:
Inglês
Revista:
Allergol. immunopatol
Ano de publicação:
2016
Tipo de documento:
Artigo
Instituição/País de afiliação:
Pontifícia Universidade Católica do Rio Grande do Sul/Brazil